Stock Market Update - January 7, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. SMX - SMX (Security Matters) Public Limited Company
Price: $33.96 | Change: +76.14% ($14.68)
SMX saw a significant 76.14% gain, with shares more than doubling around January 8, 2026. This surge came after the company unveiled its ambitious 2026 plans to scale its blockchain-based Plastic Cycle Token traceability system. Investors reacted positively to SMX's detailed goals for expanding the real-world deployment of its molecular identity technology.
The company's strategic focus on addressing the growing global demand for regulatory-grade material verification was a key driver. SMX's technology embeds invisible markers into materials, creating a tamper-resistant digital identity to track items through the supply chain. This helps businesses comply with increasing regulations and carbon-reduction targets, particularly for plastics. What's particularly interesting is the company's expansion into new industries, having recently extended its services to the cannabis, latex, and rubber glove markets, with plans to enter the denim sector in early 2026.
2. RGC - Regencell Bioscience Holdings Limited
Price: $52.88 | Change: +60.10% ($19.85)
RGC recently soared with an impressive 60.10% gain, catching the attention of many investors. However, this dramatic price movement wasn't driven by any specific new company developments or positive financial reports. Instead, the surge appears to be largely a result of speculative trading and heightened interest from individual retail investors.
Regencell Bioscience Holdings, a company focused on Traditional Chinese Medicine, currently operates with limited commercialized products. The stock has a well-known history of extreme volatility, experiencing a "135% surge" over just three sessions in the lead-up to these latest gains. With analyst sentiment generally holding a "Sell" rating, RGC stands out as a highly speculative asset, often favored by momentum traders rather than those looking at traditional business fundamentals.
3. NVVE - Nuvve Holding Corp.
Price: $3.51 | Change: +59.55% ($1.31)
NVVE soared with an impressive 59.55% gain following a significant announcement from Nuvve Holding Corp. Around January 8, 2026, the company's Japanese subsidiary, Nuvve Japan K.K., revealed it had secured a deal to install and operate a 2 MW / 8 MWh grid-scale battery energy storage system in Japan. This news sent shares climbing dramatically, jumping 61.16% on January 7 alone.
This new project, slated to begin commercial operations in November 2026, aims to strengthen Japan's power grid and integrate more renewable energy sources. Nuvve plans to leverage its established platform, which is designed for managing both electric vehicles (EVs) and stationary batteries.
What makes this particularly interesting is CEO Gregory Poilasne's highlight that this project, alongside other European battery initiatives, is expected to generate a robust and expanding revenue stream for the company into late 2026 and early 2027, signaling a positive outlook for Nuvve's future operations.
4. CELG-RI - Bristol-Myers Squibb Company Ce
Price: $0.111 | Change: +58.80% ($0.0411)
CELG-RI just rocketed 58.80% following a significant legal development that has investors buzzing. This surprising surge is tied to Contingent Value Rights (CVRs) issued during Bristol-Myers Squibb's 2019 acquisition of Celgene. These CVRs were essentially promises for future payouts, but they officially expired worthless in 2020 after key drug approval deadlines were missed.
However, a U.S. judge recently ruled on December 1, 2025, that Bristol-Myers Squibb must face a $6.7 billion lawsuit. This lawsuit, brought by CVR holders, alleges the company intentionally delayed approvals, breaching its contract. This decision has sparked renewed speculative optimism that CVR holders might receive a payout through a settlement or favorable judgment, despite the CVRs having no value under their original terms.
What's fascinating here is that the stock's dramatic climb isn't based on new drug developments or company fundamentals, but purely on the potential outcome of this high-stakes legal battle. It's a prime example of how unexpected legal twists can create speculative value where none existed before.
5. LUCY - Innovative Eyewear, Inc.
Price: $1.74 | Change: +47.46% ($0.56)
LUCY saw an impressive 47.46% gain, primarily driven by strong preliminary sales results for the fourth quarter and full year of 2025. Innovative Eyewear, Inc. announced Q4 2025 sales of approximately $1.0 million, a significant 45% increase over the previous year, with full-year sales hitting an estimated $2.7 million—a substantial 65% growth from 2024.
Adding to the positive momentum, several key executives, including the CEO and CFO, declared their intention to purchase company shares in the open market. This planned insider buying is often seen as a strong vote of confidence in the company's strategic direction and long-term prospects. The company also highlighted its claimed 44% market share of smart safety glasses on Amazon.com and optimism for securing new retail placements in 2026.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.